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Hodgkin’s disease (HD) is a lymphoid neoplasm characterized by
a low frequency of malignant Hodgkin and Reed–Stemberg (HRS)
cells in an abundant background of reactive inflammatory cells.
Active accumulation of these reactive cells, which include
lymphocytes, eosinophils, monocytes, neutrophils and fibroblasts,
is dependent upon antigen presentation and activation of HRS
cells and bystander reactive cells (Gruss et al, 1997). In the
majority of cases HRS cells are believed to derive from germinal
centre or post-germinal centre B cells that carry non-functional VH
gene rearrangements, suggesting that HRS cells can bypass the
apoptosis that would otherwise eliminate B cells with defectively
rearranged Ig genes (Hummel et al, 1995; Kanzler et al, 1996). 
In a variable percentage of cases, Epstein–Barr virus (EBV)
latent infection is detectable in the malignant HRS cells of HD.
Involvement of EBV in the pathogenesis of HD had been
suggested indirectly by serological and epidemiological studies
(Levine et al, 1971; Gutensohn and Cole, 1980; Mueller et al,
1989). Subsequently, direct evidence of EBV in tumour tissue was
established by Southern blot (Weiss et al, 1987) and polymerase
chain reaction (PCR) analysis (Shibata et al, 1991), although
neither method was able to localize EBV to specific cell types.
Later, the development of in situ hybridization for the detection of
the highly abundant EBV early RNAs (EBERs) (Glickman et al,
1988; Wu et al, 1990) and immunohistochemistry for the EBV-
encoded latent membrane protein-1 (LMP1) (Pallesen et al, 1991;
Murray et al, 1992) enabled the localization of EBV to the malig-
nant HRS cells. Although EBV can also be detected in rare non-
malignant ‘bystander’ lymphocytes within HD tissues, it is the
detection of EBV within HRS cells that is necessary to establish a
HD case as ‘EBV-associated’. 
LMP1 has many of the characteristics of a classical oncogene
and in particular is transforming when transfected into rodent
fibroblasts (Wang et al, 1985). In B-lymphocytes, LMP1 is able to
upregulate a number of cellular genes, including the apoptosis-
inhibiting bcl-2 gene (Henderson et al, 1991; Wang et al, 1996) as
well as inducing IL-10, a potent inhibitor of T cell activation
(Nakagomi et al, 1994). The transforming effects of LMP1 and its
particularly high level expression in the HRS cells of EBV-asso-
ciated HD indicate a role for this protein in the pathogenesis of
EBV-positive HD and suggest important biological differences in
HD that may be dependent upon EBV status (Oudejans et al,
1997). 
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Summary We have examined expression of the Epstein–Barr virus (EBV) latent membrane protein-1 (LMP1) in the malignant Hodgkin 
and Reed–Sternberg (HRS) cells of Hodgkin’s disease (HD) and its impact on response to treatment and on survival. Paraffin tissue from 100
adult immunocompetent patients with HD were analysed using immunohistochemistry to identify LMP1 expression. According to the Rye
classification, 8% of patients had lymphocyte predominance (LP) subtype, 48% had nodular sclerosis (NS) disease, 37% were of the mixed
cellularity (MC) subtype and 7% were of the lymphocyte depletion (LD) subtype. During the five year follow-up period 27 patients died and 74
patients achieved a complete remission. Patients with LD subtype were older (P = 0.03), less frequently achieved complete remission (P =
0.01), had shorter disease-free survival (P = 0.01) and overall survival (P = 0.002) compared with the other subtypes of HD. LMP1 expression
was found in the tumour cells of 26% of cases of HD. LMP1 expression was less common in NS disease than in the other subtypes (P = 0.05),
whereas an association between MC subtype and LMP1 expression was not found (P = 0.22). Using the log-rank test there were no
differences in overall survival or disease-free survival based on EBV status either when all patients were analysed or when LD and LP
subtypes were excluded. However, the presence of EBV was associated with significantly longer disease-free survival in the subgroup of
patients ≤ 30 years old (P = 0.02) and in those patients ≤ 34 years old (P = 0.05). In contrast, there was a trend for shorter disease-free
survival for EBV-positive patients in the subgroup > 35 years old, but this difference was not statistically significant (P = 0.11). A similar trend
was observed in patients > 50 years old. Analysis of the impact of LMP1 expression in patients who had different stage and B symptoms
status showed that expression of EBV was associated with longer disease-free survival (P = 0.019) in early stage (1 + 2) patients without B
symptoms. Significant differences in the other subgroups based on EBV status was not found. Factors adversely affecting the likelihood to
achieve a complete remission were: absence of LMP1 expression (OR 6.4, 95% Cl 1.07–38.5, P = 0.04), age (OR 1.68, 95%Cl 1.15–2.5, 
P = 0.007) and subtype of HD (OR 3.32, 95%Cl 1.11–9.94, P = 0.03). Age and subtype of HD had an independent impact on overall survival
(P = 0.01). We conclude that expression of LMP1 in HRS cells has a favourable impact on prognosis for HD patients, but that this effect may
be restricted to young adult patients and those with early stage disease. © 2001 Cancer Research Compaign. http://www.bjcancer.com
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Initial studies investigating the impact of EBV on clinical
outcome did not find any correlation between EBV status and
survival in HD patients (Fellbaum et al, 1992; Vestlev et al, 1992;
Claviez et al, 1994), although the first of these studies used PCR to
detect the virus. Recent larger Spanish and English studies
(Morente et al, 1997; Murray et al, 1999) have demonstrated a
significant association between detection of EBV in HRS cells and
longer overall survival and disease-free interval, respectively.
However, two other studies have indicated no effect of EBV status
on clinical features or outcome in HD patients (Enblad et al, 1997;
Axdorph et al, 1999). In the present study we have examined the
influence of EBV LMP1 expression on clinical outcome in a series
of HD patients from Croatia. Clinical outcome was determined by
3 measures: complete remission, disease-free survival time and
overall survival time, as defined previously (Kaufman and Longo,
1992). 
MATERIALS AND METHODS 
Our initial study group comprised 143 consecutive patients diag-
nosed with HD between 1980 and 1990 in the Institute of
Pathology, Clinical Hospital Center Rebro, Zagreb and the
Department of Pathology, University Hospital, Split. Clinical data,
including treatment and outcome (complete remission, disease-
free survival and overall survival in a 5 year follow-up period)
were retrieved from the patients’ hospital records. After clinico-
pathologic staging, all patients were treated by the MOPP/ABVD
chemotherapy protocol and radiotherapy if necessary. 43 patients
were excluded from the study because of incomplete clinical data
or insufficient material remaining in the tissue block to allow the
EBV status to be determined. The remaining 100 patients were
grouped according to the Rye classification as LP, NS, MC or LP
subtype. Tumour tissue had been fixed in 10% buffered formalin,
dehydrated in gradients of ethanol, cleared in xylene and
embedded in paraffin wax. 
Before the immunohistochemical assay, 4-micrometre paraffin
sections were prepared, deparaffinized, hydrated and washed in
Tris-buffered saline (TBS, pH 7.6). Immunohistochemistry for
LMP1 was performed using a mouse monoclonal antibody to
LMP1 (CS1-4, Dako, Glostrup, Denmark) and labelled streptav-
idin biotin detection kit, LSAB+ (Dako, Glostup, Denmark). Prior
to immunohistochemistry, sections were washed in TBS and pre-
treated for 3 ´ 5 minutes in a microwave oven at maximum power.
Negative controls for immunohistochemistry were consecutive
test sections in which primary antibody was replaced with non-
immune serum of the same IgG subclass. 
For statistical analysis, c2 test and Fisher’s test were used to
compare categorical variables. The Student t-test and
Mann–Whitney test were used to compare continuous variables.
The survival of different groups was analysed by the use of
Kaplan–Meier curves and the log-rank test. Overall survival was
calculated as the time from diagnosis to death from any cause or to
the date of the last known follow up. For patients who responded
to therapy, disease-free interval was determined as the time from
achieving a complete remission to relapse, death from any cause or
the end of follow up. For patients who did not respond to chemo-
therapy, disease-free interval was recorded as zero. Patients were
also grouped according to early versus late stage disease +/– the
presence of B symptoms, and the influence of EBV status on
disease-free survival in each of these groups was assessed.
Multivariate logistic regression analysis was used to identify the
factors that were of independent significance in the failure to
achieve complete remission. Multivariate Cox’s regression anal-
ysis was used to identify the factors that impacted on overall
survival. The following variables: gender, age in decade intervals
from < 20 to < 60 years old, subtype of HD (LP, NS, MC), stage
(1, 2, 3, 4), presence of B symptoms (present or absent) and LMP1
expression (positive or negative) were included in these analyses.
A difference of P = 0.05 or less was considered significant. 
RESULTS 
Among the 100 eligible patients, 52% were male and 48% were
female. The mean age of all patients was 40 years (range 13–84
years). The age distribution was bimodal with 63% patients under
40 years and 25% older than 50 years. In the 5-year follow up
period 27 patients had died and 74 patients achieved a complete
remission. According to the Rye classification, 8% of patients
were of LP subtype, 48% had NS disease, 37% were of MC
subtype and 7% were of LD subtype. Patients with LD disease
were older than patients with other subtypes (P = 0.03). LD
patients also achieved a complete remission less frequently (P =
0.01), had a a shorter disease-free survival (P = 0.01) and a lower
overall survival (P = 0.002) than the other subtypes which showed
no difference in these variables. The presence of latent EBV infec-
tion was detected by immunohistochemistry for LMP1 in 26/100
(26%) cases. Table 1 shows the relationship between the presence
of EBV and clinical characteristics such as age, histologic subtype,
stage, presence of B symptoms, complete remission, disease-free
survival and overall survival. Patients with the NS subtype were
more often LMP1-negative (P = 0.05), but a significant associa-
tion between patients with the MC subtype and the presence of
EBV was not found (P = 0.22). 
Outcome analysis according to EBV status was performed on
all patients and also when the LD and LP subtypes were excluded.
The distinction between non-Hodgkin’s lymphoma and LD HD is
not clear cut and LP cases were excluded as this disease has been
shown to differ morphologically, immunophenotypically and clin-
ically from classic HD (Linden et al, 1988; Harris et al, 1994)
(Stoler et al, 1995). Using the log-rank test, we did not find any
statistically significant differences in overall survival based on
EBV status (Figure 1A and 1B). No significant differences were
observed in disease-free survival based on EBV status when all
patients were analysed (P = 0.48) or when the LP and LD subtypes
were excluded (P = 0.46) (Figures 2A and 2B). However, when the
effect of EBV status was examined within different age groups,
longer disease-free survival was observed in LMP1-positive
patients  ≤ 30 years old (P = 0.02) as well as in patients ≤ 34 years
old (P = 0.05) (Figures 3A and 3B). In contrast, within the group
of older patients (> 35 years), those with LMP1 negative disease
had longer disease-free interval, although this difference did not
reach statistical significance (P = 0.11) (Figure 3C). There were
insufficient numbers to assess the impact of EBV status in the
small subgroup of 10 patients > 50 years old who achieved
complete remission. However, longer survival of LMP1-negative
patients in this group (36.6 ± 14 months versus 22.6 ± 42 months)
was noted. 
Table 2 shows the distribution of LMP1 expression according to
early (1 + 2) and late (3 + 4) stages of HD and the presence of B
symptoms. When disease-free survival was analysed in a subset of
29 patients with early stage (1 + 2) HD without B symptoms it was
shown that EBV-positive patients in this subgroup had significantlyPrognostic impact of EBV expression in HD 1229
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Table 1 Differences in variables according to LMP1 expression 
Variable Cases EBV+ EBV– Test P
No 52 16 36 log rank 0.12 
Yes 48 8 40 log rank 0.33 
1 3 14 
2 10 15 
31 0 3 3 c2 0.11 
4 3 12 
1+2 42 13 29 log rank 0.48 
3+4 58 13 45 log rank 0.87 
LP 8 3 5 
NS 48 9 39 c2 0.05 
MC 37 11 26 c2 0.22 
LD 7 3 4
No 26 4 22
Yes 74 22 52 c2 0.15 
NS+MC 65 63.1 ± 36.9 51.6 ± 38 log rank 0.46 
All subtypes 74 59.5 ± 41.2 53 ± 36.9 log rank 0.48 
≤ 30 33 94 ± 36 44 ± 36.5 log rank 0.02 
Age(years) ≤ 34 37 85.4 ± 40 48 ± 37.8 log rank 0.05 
> 35 31 45.5 ± 35.7 61.45 ± 34.8 log rank 0.11 
> 50 10 22.6 ± 42 36.6 ± 14
NS+MC 65 116 108 log rank 0.30 
All subtypes 100 76 77 log rank  0.97 
*Mean. 
Age (years*) 100 42.1 ± 17 36.06 ± 17 Mann  0.34 
Whitney
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Figure 1A Overall survival in all subtypes of HD according to LMP 1
expression 
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Figure 1B Overall survival in NS and MC subtypes of HD according to LMP 1
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longer disease-free survival (P = 0.019) (Figure 4). Such signifi-
cant differences were not observed in other subgroups divided by
stage and B symptoms. 
According to the multivariate regression analysis (Table 3),
those characteristics which independently influenced the failure to
achieve complete remission were: absence of LMP1 expression
with odds ratio 6.4 (95%CI 0.024–0.89, P = 0.04), subtype of HD
with odds ratio 3.32 (95%CI 1.11–9.94 P = 0.03) and older age in
decade intervals with odds ratio 1.68 (95%CI 1.15–2.5 P = 0.007)
(Table 3). Cox’s regression analysis model showed that older age
(RR 2.75 95% CI 1.55–4.85 P = 0.001) and HD subtype (RR 1.8
95% CI 1.06–2.98 P = 0.03) also negatively influenced overall
survival. 
DISCUSSION 
This study presents the first analysis of EBV expression in HD
from Croatia. We observed a bimodal age distribution as well as a
predominance of the NS and MC subtypes (together comprising
85% of all cases). Such distributions are in accordance with data
from developed countries (MacMahon, 1966; Glaser and Jarrett,
1996). Our results also confirm that LD HD is more common in
older people and that this subtype is associated with adverse
outcome, both in terms of lower complete remission rate and
shorter disease free interval (Kaufman and Longo, 1992). 
In the last few years, a number of studies from around the world
have confirmed the presence of the EBV genome and expression
of the EBV-encoded oncogene, LMP1, in the HRS cells of a
proportion of HD patients. The frequency with which EBV is
demonstrated in HD tumours shows geographical variability
(Glaser and Jarrett, 1996; Glaser et al, 1997). Among Croatian
adult patients with HD, we have demonstrated LMP1 expression
in 26% of cases. This frequency is similar to that reported from
other European countries (Pallesen et al, 1991; Herbst et al, 1992;
Hummel et al, 1992; Murray et al, 1992; Glaser et al, 1997),
including a study from Poland (Kordek et al, 1996). We have
confirmed previous data showing that the NS subtype is often
EBV negative (Jarrett et al, 1991; O’Grady et al, 1994). Although
MC HD is considered to be an EBV-related disease, we did not
find a significant association between LMP1 expression and MC
disease. There have been few reports of the incidence of EBV in
HD from Eastern Europe. In one Czech study MC rates of only
38% were recorded (Macak et al, 2000), although other studies
from Poland (Kordek et al, 1996) have indicated higher EBV-posi-
tive rates for MC disease. Clearly, further larger samples are
required to establish whether this and other studies reporting low
EBV-positive rates for MC disease are outliers or are representa-
tive of true regional differences. 
There are conflicting reports on the effect of EBV status on
outcome in HD. Although two recent studies have shown no effect
of EBV on outcome (Enblad et al, 1997; Axdorph et al, 1999)
other studies have demonstrated that the presence of EBV in HRS
cells is associated with a favourable outcome. Thus, two previous
studies of adult HD from developed populations, have demon-
strated improved overall survival (Morente et al, 1997) and higher
complete response rates together with significantly longer disease-
free interval (Murray et al, 1999) for patients with EBV-positive
HD tumours. A more recent study of adult patients from India also
showed that 10-year relapse-free survival was significantly higher
for EBV-positive HD patients when compared to the EBV-nega-
tive group (Naresh et al, 2000). A second smaller study from South
Africa of 36 children with HD showed that EBV-positive HD was
associated with longer median survival times (Engel et al, 2000). 
Our results showed that there were no statistically significant
differences in stage, presence of B symptoms, as well as complete
remission, disease-free survival and overall survival according to
LMP1 expression either when all patients were examined or when
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Figure 2A Disease-free survival in all subtypes of HD according to LMP 1
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Table 2 LMP1 expression according to stage and B symptoms 
B symptoms 
LMP1 expression Stage No Yes Total 
1 + 2 21 8 29 
3 + 4 13 32 45 
1 + 2 10 3 13 
3 + 4 8 5 11 
Negative
PositivePrognostic impact of EBV expression in HD 1231
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LP and LD subtypes were excluded from the analysis. However,
when the patients were subgrouped according to age, significantly
longer disease-free survival was observed in LMP1-positive
patients  ≤ 30 years old as well as in patients ≤ 34 years old but not
in older patients (> 35 years) where a non-significant trend
towards longer disease-free survival of EBV-negative patients
appeared. LMP1-negative patients aged >50 years also appeared to
have longer disease-free survival indicating that reversal of the
beneficial effect of EBV which seemed to occur after 35 years
might also extend into the older age groups. This finding is
supported by recent data from Glaser’s group (Clarke et al, 2000)
who assayed the EBV status of 311 women with Hodgkin’s
disease. In contrast to women in the 19–44 age group, older
women (aged 45–79) with EBV-positive disease had significantly
poorer survival than their EBV-negative counterparts. Clearly, a
further study with sufficient numbers of cases in each age group is
required to substantiate these trends. Furthermore, when the
patients were subgrouped according to stage and presence of B
symptoms, patients in early stage (1 + 2) disease without B symp-
toms had significantly better disease-free survival if they had
LMP1-positive HRS cells. Overall, these data suggest that the clin-
ical effects of EBV may be different at different ages or between
different prognostic subgroups. 
Despite these differences based on age and stage, EBV appeared
to have an overall beneficial impact in our study population where
failure to achieve complete remission was significantly associated
with absence of LMP1 expression with odds ratio 6.4. At the
present time we cannot precisely determine the factors that are
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responsible for the observed differences in prognosis between
EBV-positive and -negative patients. Naresh et al (2000) have
suggested that higher PCNA values in EBV-positive HRS cells
may make them more responsive to chemotherapy- and radio-
therapy-associated DNA damage. That HRS cells carrying the
EBV genome might be more sensitive to chemotherapy-induced
apoptosis is also supported by the observation that bcl-2 is often
overexpressed in EBV-negative, but not EBV-positive HRS cells
(Jiwa et al, 1995) – a somewhat surprising finding when one
considers the strong anti-apoptotic effects of LMP1 in vitro
(Henderson et al, 1991; Wang et al, 1996). 
LMP2 is also expressed by EBV-positive HRS cells (Niedobitek
et al, 1997; Murray et al, 1998) and together with LMP1 is a target
for cytotoxic T cells in association with different MHC class I
restriction elements in vitro (Khanna et al, 1998; Lee et al, 1998).
In vitro studies also show that HD cell lines can process and
present epitopes from LMP1 and LMP2 in the context of multiple
class I alleles and are sensitive to lysis by EBV-specific CTLs
(Sing et al, 1997; Lee et al, 1998). Furthermore, EBV-specific
CTLs can be generated from patients with HD, albeit at lower
frequency than normal controls, and such cells survive and have
antiviral activity in vivo (Roskrow et al, 1998). Thus, it is possible
that the presence of EBV in HRS cells is able to elicit an immune
response, which may in turn limit disease progression. These
results are interesting since EBV-positive cases of HD have been
shown to contain significantly more activated CTLs and express
relatively higher levels of MHC class I than EBV-negative cases
(Oudejans et al, 1996; Lee et al, 1998; Murray et al, 1998) Despite
this, other studies have suggested that EBV-infected HRS cells
may be unable to stimulate an effective anti-EBV CTL response.
This is based on the observation that tumour-derived T lympho-
cytes from EBV-negative HD show EBV-specific cytotoxicity,
whereas corresponding lymphocytes from EBV-positive HD
lesions do not (Frisan et al, 1995), and is supported by the frequent
overexpression of IL-10 in EBV-infected H-RS cells but not their
EBV-negative counterparts (Herbst et al, 1996; Dukers et al,
2000). 
It is possible that within the young adult group there is a benefi-
cial EBV-specific immune response to the tumour cell population.
In older patients this response may be less effective or other nega-
tive prognostic influences may override any beneficial effect EBV
may have. The beneficial effects of EBV may also be more
obvious in early stage disease and in ‘A’ patients where markers of
poor prognosis are absent. The clinical effects of EBV in HD are
therefore likely to be subtle and divergent in different subgroups of
patients. This could well account for previous conflicting results,
particularly when the majority of such studies have included small
numbers or when the patients’ treatment has been heterogeneous.
Further studies are clearly required to establish the underlying
biology responsible for the differing clinical effects of EBV in HD
patients. 
Table 3 Factors influencing failure to achieve a complete remission 
Variable Reference level OR 95% Cl P
Positive  LMP1 expression positive 6.4 1.07–38.5 0.04 
Negative 
NS
MC LP subtype 3.32 1.11–9.94 0.03 
LD
< 20 
21–30 
31–40 
41–50 < 20 years 1.68 1.15–2.5 0.007 
51–60
>6 1
Model c2 = 22.6, P = 0.01. OR = odds ratio. Cl = confidence interval. 
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Figure 4 Disease-free survival in early stages (1 + 2) of HD without B
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